Back HIV/AIDS

HIV / AIDS

IDWeek 2015: Studies Continue to Support Tenofovir Alafenamide as it Nears Approval

A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression when switching from other combinations and was associated with improved kidney function and bone health, according to studies presented at IDWeek 2105 last week in San Diego. Other research showed that the new formulation works better than the old one for black patients and for older people, and that it can be safely used with sofosbuvir/ledipasvir (Harvoni) for hepatitis C treatment.

alt

IAPAC Summit: At Least 25,000 People in the U.S. May Now Be Using PrEP

As many as 30,000 people in the U.S. may now be taking pre-exposure prophylaxis (PrEP) to prevent HIV, researchers reported at the 4th IAPAC Controlling the HIV Epidemic with Antiretrovirals summit in Paris last week. Meanwhile, as the summit also heard, European and other countries face frustrating delays in securing access to PrEP.

alt

ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients

Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.

alt

U.S. Physicians Routinely Offer Early HIV Treatment, But Only a Third Have Prescribed PrEP

Most doctors at the frontline of the HIV epidemic in the United States recommend early antiretroviral therapy (ART) and many also believe they have a role in providing pre-exposure prophylaxis (PrEP) to the uninfected partners of their patients living with HIV, according to research published in the online edition of Clinical Infectious Diseases. Overall, 87% of doctors recommended ART from the point of diagnosis and most thought PrEP was appropriate in some circumstances. However, only a third had actually prescribed PrEP.

alt

IDWeek 2015: Affordable Care Act Coverage Improves Chances of HIV Viral Suppression

Enrolling low-income and under-insured people with HIV in an Affordable Care Act (ACA) health plan improves their odds of having sustained antiretroviral treatment and undetectable viral load, according to a presentation at ID Week 2015 in San Diego. This study adds to the recent evidence confirming the benefits of providing healthcare coverage for people living with HIV.

alt

IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study

Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.

alt

Certain Vaginal Bacteria May Protect Against HIV Transmission During Sex

Specific types of Lactobacillus bacteria in the vaginal mucus can trap HIV and may help prevent sexual transmission of the virus to women, according to a report in the October 6 edition of the online journal mBio. Conversely, researchers found that another species associated with bacterial vaginosis may increase susceptibility to HIV infection.

alt